Dr. Patrick Y. Wen

• 
  www.38lemon.com/dailyjournal.php?y=2008&m=05&d=22 - [Cached Version]
  Published on: 5/22/2008    Last Visited: 2/3/2009  

  "It's really hard to think of anyone who's helped biomedical research in this country or the National Institutes of Health more than he has, and hopefully he'll get some benefit from how he's helped others," said Dr. Patrick Wen, clinical director of the Center for Neuro-oncology at the Dana-Farber Cancer Institute.
  ...
  "Because the numbers are relatively small," Wen said, "the incentive to develop drugs for brain tumors is less than for breast cancer or prostate cancer."

• 
  www.dana-farber.org/pat/adult/neuro%2Doncology/treatmen - [Cached Version]
  Published on: 1/10/2010    Last Visited: 1/10/2010  

  Patrick Wen, MD

• 
  www.uptodate.com/home/clinicians/toc.do?tocKey=table_of - [Cached Version]
  Last Visited: 1/3/2010  

  Patrick Y Wen, MD Editor - Neurooncology Associate Professor of Neurology Harvard Medical School
  ...
  Patrick Y Wen, MD Editor - Neurooncology Associate Professor of Neurology Harvard Medical School

• 
  www.usobserver.com/archive/july-08/cancer-cash-cow.htm - [Cached Version]
  Published on: 7/1/2008    Last Visited: 8/22/2008  

  According to Dr. Patrick Wen, clinical director of the Center for Neuro-oncology at the Dana-Farber Cancer Institute in Boston, in regards to Sen.

• 
  www.wowt.com/news/headlines/19102364.html - [Cached Version]
  Published on: 5/20/2008    Last Visited: 5/21/2008  

  "The older you are the worse the outcome," said Dr. Patrick Wen, associate professor of neurology at Harvard Medical School.

• 
  www.ctf.org/clinical_trials/gleevecmeningioma.htm - [Cached Version]
  Published on: 2/1/2003    Last Visited: 3/1/2006  

  Patrick Y. Wen, MD 617-632-2166 patrick wen@dfci.harvard.edu
  ...
  Patrick Y. Wen, MD, Study Chair, Dana-Farber/Harvard Cancer Center

• 
  www4.netrition.com/cgi/news.cgi?file=20080520224000_0 - [Cached Version]
  Published on: 6/10/2008    Last Visited: 6/10/2008  

  It cannot eliminate a tumor, said Dr. Patrick Wen, clinical director of the center for neuro-oncology at Dana Farber Cancer Institute, but "it buys time."
  ...
  Also, Wen said, patients usually undergo chemotherapy in pill form, for as long as six months to a year.He said the pills, called Temodol, were "relatively well tolerated," but they can occasionally cause side effects, such as lowered blood counts, leaving patients tired and susceptible to infections.
  
  Specialists said it is almost certain that sophisticated genetic analyses of Kennedy's tumor will be done to tailor treatments so they are most effective.
  
  There has been some recent progress toward new treatments for malignant gliomas, Wen and others said.

• 
  www.intelihealth.com/IH/ihtIH/WSIHW000/333/8012/725566. - [Cached Version]
  Published on: 5/22/2008    Last Visited: 6/6/2008  

  "It's really hard to think of anyone who's helped biomedical research in this country or the National Institutes of Health more than he has, and hopefully he'll get some benefit from how he's helped others," said Dr. Patrick Wen, clinical director of the Center for Neuro-oncology at the Dana-Farber Cancer Institute.
  ...
  "Because the numbers are relatively small," Wen said, "the incentive to develop drugs for brain tumors is less than for breast cancer or prostate cancer."
  
  After so many years of having few options for their patients, cancer doctors in 2005 added an important new weapon.

• 
  www.usatoday.com/news/washington/2008-05-20-kennedy-tum - [Cached Version]
  Published on: 5/20/2008    Last Visited: 5/21/2008  

  Patrick Wen, a brain cancer specialist at Boston's Dana-Farber Cancer Institute, says the outlook for patients with gliomas can vary greatly depending on the type of malignancy.Patients with grade IV glioblastoma generally survive about 15 months, Wen says, compared to two to four years for patients with the less-common grade III anaplastic glioma.

• 
  abc2.org/research/annual-scientific-meeting/attendees - [Cached Version]
  Last Visited: 10/6/2009  

  Dr. Patrick Wen
  
  Clinical Director, Neuro-Oncology Program
  
  Dana-Farber Cancer Institute, Harvard Medical School

Page:  1 2 3 4 5